Accueil > RECHERCHE > Matière excitée et défauts > Equipe ARIA > Activités de recherche

Activités de recherche

publié le , mis à jour le

Healthy tissues preservation and patient recovery without sequelae are key factors in modern cancer radiation-therapy. Given the biophysical and biological characteristics of C-ion beams, C-ion radiotherapy has the potential to improve local control and reduce normal tissue complications in the treatment of cancer patients, especially those with radio-resistant solide tumours that have poor outcomes with standard therapies.

Radiobiology of resistant cancers and benefit of hadrontherapy : role of oxidative stress, DNA repair mechanisms and cell communications
• Identification of responsible mechanisms of cancer stem cell survival after photon and hadron irradiation with focus in DNA repair and antioxidant system
• Cell communications : Bystander signaling effect
• Engineering of new in vitro 3D models for radiobiology : 3D printing, spheroids, organoids
Identification of biomarkers of individual sensitivity to radiotherapy
• To identify new mechanisms and new biomarkers of adverse health effects
• To develop and implement appropriate bioinformatical methodologies for validation of biomarkers

ONGOING PROJECTS :

- HABIONOR = HAdronBIOlogie en NORmandie :
Programme de recherche en Radiobiologie pour l’hadronthérapie au centre ARCHADE
ARIA group is partner (contact person= F. Chevalier)
2018-2020 ; Funded by the Normandy Region

- ONCOTHERA = Constitution d’un Réseau Normand d’innovations thérapeutiques en oncologie
Cimap (ARIA, AMA, MADIR) is partner (contact person= F. Chevalier)
2019-2020 ; Funded by the Normandy Region

- HARMONIC = Health effects of cardiac fluoroscopy and modern radiotherapy in paediatrics
ARIA group is partner (contact person= S. Haghdoost)
2019-2024 ; Funded by the European Union

- FIDIA2C = Effets des Faibles doses d’Irradiation sur le DIAlogue Cellules normales / Cellules tumorales
ARIA group is partner (contact person= F. Chevalier)
2019-2020 ; Funded by the Brancusi exchange between France and Romania

- CANCERS ET EFFET BYSTANDER
ARIA group is partner (contact person= F. Chevalier)
2019-2021 ; Funded by CEA / EDF

- RADIOSUSCEPTIBILITÉ INDIVIDUELLE
ARIA group is partner (contact person= S. Haghdoost)
2019-2021 ; Funded by CEA / EDF

- ARCHADE-CHOxTRaCC = Recherche de combinaisons thérapeutiques hadronthérapie - thérapies ciblant la radiorésistance biologique liée à l’hypoxie et au stress oxydant tumoral.
ARIA group is leader (contact person= S. Haghdoost)
2020-2022 ; Funded by the Normandy Region

- HADRON3D = Hadrontherapy in 3D multicellular models of radioresistant tumors : towards new therapeutic strategies
2019-2024 ; not funded (contact person= F. Chevalier)